CADTH does not accept new evidence demonstrating SPINRAZA™’s effectiveness and safety for treating SMA – a progressive, life-altering neurodegenerative disease SMA treatment access remains unequal across Canada , with only Quebec funding SMA care for patients over 18 Implementing the draft recommendation would put Canada’s health system out of step with those of over 25 countries, which fund treatment access for adult SMA patients TORONTO , May 20, 2022 /CNW/ – Biogen Canada is deeply disappointed for the SMA community due to the draft recommendation from the Canadian Agency for Drugs and Technologies in Health (CADTH) that has advised against SPINRAZA™ (nusinersen …
Read the source article at Cision
2022-05-20 11:00:00
